<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25327" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mucosa-Associated Lymphoma Tissue (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mullangi</surname>
            <given-names>Sanjana</given-names>
          </name>
          <aff>Hillcrest Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lekkala</surname>
            <given-names>Manidhar Reddy</given-names>
          </name>
          <aff>University of Rochester Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sanjana Mullangi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manidhar Reddy Lekkala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>18</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25327.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Mucosa-associated lymphoid tissue (MALT) lymphoma is a subtype of the marginal zone lymphoma (MZL), which is non-Hodgkin lymphoma. It is also called extranodal marginal zone lymphoma (EMZL). It is frequently noted in the stomach but virtually can involve any mucosal site like the salivary gland, ocular adnexa, lung, and elsewhere. EMZL is clinically distinct from the other types of MZL, the splenic marginal zone lymphoma (SMZL), and the nodal marginal zone lymphoma (NMZL) with specific diagnostic criteria, clinical behavior, different genetic features, and therapeutic implications.<xref ref-type="bibr" rid="article-25327.r1">[1]</xref>&#x000a0;Other commonly used terminologies for MALT lymphoma are &#x0201c;MALToma,&#x0201d; &#x0201c;MALT-type lymphoma,&#x0201d; and &#x0201c;pseudo-lymphoma.&#x0201d; In this review, we interchangeably use MALT lymphoma with EMZL.</p>
      </sec>
      <sec id="article-25327.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>MALT lymphoma is the commonest MZL type and&#x000a0;has been described in all tissues.<xref ref-type="bibr" rid="article-25327.r2">[2]</xref>&#x000a0;They arise from the lymphoid populations induced by chronic inflammation in extranodal sites. The most commonly affected organ is the stomach, associated with chronic gastritis induced by <italic toggle="yes">Helicobacter pylori</italic>.<xref ref-type="bibr" rid="article-25327.r3">[3]</xref>&#x000a0;</p>
        <p>There is an emerging role of infectious etiologies in the pathogenesis of EMZL. Other bacterial infections found to be implicated in the pathogenesis of EMZL are <italic toggle="yes">Borrelia burgdorferi</italic> in MZL arising in the skin,&#x000a0;<italic toggle="yes">Chlamydophila psittaci</italic> in ocular adnexa,&#x000a0;<italic toggle="yes">Campylobacter jejuni</italic> in the small intestine,&#x000a0;and possibly <italic toggle="yes">Achromobacter xylosoxidans</italic> in lung MZL.<xref ref-type="bibr" rid="article-25327.r4">[4]</xref><xref ref-type="bibr" rid="article-25327.r5">[5]</xref><xref ref-type="bibr" rid="article-25327.r6">[6]</xref><xref ref-type="bibr" rid="article-25327.r7">[7]</xref>&#x000a0;Chronic hepatitis C virus (HCV) has also been implicated to be a high risk in the development of EMZL.<xref ref-type="bibr" rid="article-25327.r8">[8]</xref>&#x000a0;In addition to infection, chronic inflammatory conditions like autoimmune diseases can also increase the risk of development of MALT lymphoma. Patients with Sjogren syndrome have an extremely increased risk of developing an MZL.<xref ref-type="bibr" rid="article-25327.r9">[9]</xref><xref ref-type="bibr" rid="article-25327.r10">[10]</xref></p>
      </sec>
      <sec id="article-25327.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>MZL represents about 10%&#x000a0;to 15% of all non-Hodgkin Lymphomas, of which EMZLs comprise about two-thirds of cases in the western world. The stomach is the most common site, followed by ocular adnexa, lung, and salivary glands. It is usually seen in adults with the median age of diagnosis greater than 60 years.<xref ref-type="bibr" rid="article-25327.r11">[11]</xref>&#x000a0;</p>
        <p>In the United States, EMZLs comprise 5 to 10 percent of all non-Hodgkin lymphoma and comprise up to half of the lymphomas in organs such as the stomach, ocular adnexa, and lung.<xref ref-type="bibr" rid="article-25327.r12">[12]</xref><xref ref-type="bibr" rid="article-25327.r13">[13]</xref><xref ref-type="bibr" rid="article-25327.r14">[14]</xref><xref ref-type="bibr" rid="article-25327.r15">[15]</xref>&#x000a0;EMZLs occur equally among men and women, and the estimated incidence in the United States is about 18.3 cases per 1 million person-years.<xref ref-type="bibr" rid="article-25327.r11">[11]</xref>&#x000a0;</p>
        <p>Gender disparities are seen by the site of involvement, where men have common involvement of the stomach, small intestine, and skin, and women have involvement of the salivary gland, soft tissue, and thyroid gland.<xref ref-type="bibr" rid="article-25327.r11">[11]</xref>&#x000a0;A variant of EMZL called immunoproliferative small intestinal disease, or Mediterranean lymphoma primarily occurs in young adults in the middle east, Africa, and the far east.<xref ref-type="bibr" rid="article-25327.r16">[16]</xref></p>
      </sec>
      <sec id="article-25327.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>EMZL is clinically indolent and postulated to arise from the B lymphocytes of the marginal zone, which is the external part of the secondary lymphoid follicles. It is postulated that apart from the continuous antigenic stimulation, additional oncologic events, including chromosomal abnormalities, play a role at which the lymphoproliferative process eventually becomes independent of antigenic stimulation.<xref ref-type="bibr" rid="article-25327.r3">[3]</xref>&#x000a0;</p>
        <p>MALT lymphoma presents with recurrent chromosomal translocations and more frequently with gains at 3p, 6p, 18p, and del (6q23). Recent studies in MALT lymphoma have, in fact, demonstrated genetic alteration involving the NF-kB pathway, a signaling pathway involved in many cancers.<xref ref-type="bibr" rid="article-25327.r17">[17]</xref><xref ref-type="bibr" rid="article-25327.r18">[18]</xref><xref ref-type="bibr" rid="article-25327.r19">[19]</xref><xref ref-type="bibr" rid="article-25327.r20">[20]</xref><xref ref-type="bibr" rid="article-25327.r21">[21]</xref></p>
      </sec>
      <sec id="article-25327.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The morphology of EMZL typically reproduces the normal mucosa-associated lymphoid tissue, with reactive follicles with neoplastic cells occupying the marginal zone. The typical marginal zone B cells are small to medium-sized with slightly irregular nuclei and inconspicuous nucleoli. The chromatin is moderately dispersed with associated pale cytoplasm. The morphology of the malignant clone is variable, and the involved tissue usually demonstrates a polymorphous infiltrate of small lymphocytes and less frequently large, activated cells, which are by definition in the minority. The key immunophenotypic findings are the demonstration of clonality and confirmation of B cell origin. The immunophenotype also helps in the exclusion of other small B cell lymphomas like small lymphocytic lymphoma, mantle cell lymphoma, and follicular lymphoma.<xref ref-type="bibr" rid="article-25327.r22">[22]</xref>&#x000a0;</p>
        <p>EMZL tumor cells express the CD19, CD20, CD22, CD79a, which are the B-cell associated antigens as well as CD21 and CD35, which are the complement receptors. They are usually negative for CD5, CD10, CD23, BCL6, and cyclin D1. It is important that the diagnosis is confirmed by an expert hematopathologist.<xref ref-type="bibr" rid="article-25327.r23">[23]</xref>&#x000a0;Molecular techniques show a demonstration of immunoglobulin light chain restriction or clonal IgH rearrangements.</p>
      </sec>
      <sec id="article-25327.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients usually present with symptoms associated with localized disease depending on the tissue of origin or site of involvement. As mentioned previously, the stomach is the most frequent site of involvement, but it can involve other parts of the gut, ocular adnexa, lung, lacrimal and salivary glands, skin, soft tissue, thyroid, breast, and synovium, etc.<xref ref-type="bibr" rid="article-25327.r11">[11]</xref><xref ref-type="bibr" rid="article-25327.r14">[14]</xref><xref ref-type="bibr" rid="article-25327.r24">[24]</xref><xref ref-type="bibr" rid="article-25327.r25">[25]</xref><xref ref-type="bibr" rid="article-25327.r26">[26]</xref><xref ref-type="bibr" rid="article-25327.r27">[27]</xref></p>
        <p>Patients present with some of the following clinical presentations, depending on the site of involvement. The typical B symptoms noted with lymphoma are rare, seen in &#x0003c;5 percent of patients.<xref ref-type="bibr" rid="article-25327.r28">[28]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Gastric: Gastroesophageal reflux disease, stomach pain or discomfort, weight loss, anorexia, gastrointestinal bleeding, nausea, vomiting.<xref ref-type="bibr" rid="article-25327.r29">[29]</xref><xref ref-type="bibr" rid="article-25327.r30">[30]</xref>&#x000a0;<italic toggle="yes">H. pylori</italic> infection is noted in &#x0003e;90 percent of gastric MALT.</p>
          </list-item>
          <list-item>
            <p>Ocular adnexa: Irritation of the eye, slow-growing mass, redness of the eye, excessive eye-watering.<xref ref-type="bibr" rid="article-25327.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Skin: Papules, plaques, nodules, itching usually on the upper extremities and trunk.</p>
          </list-item>
          <list-item>
            <p>Lung: Asymptomatic with lung nodules or consolidative changes.</p>
          </list-item>
          <list-item>
            <p>Salivary gland: A slow-growing mass, sometimes bilateral involvement.<xref ref-type="bibr" rid="article-25327.r31">[31]</xref></p>
          </list-item>
        </list>
        <p>EMZL usually remains localized in the tissue of origin for a prolonged period of time, but sometimes the involvement of regional lymph nodes and other mucosal surfaces is noted at diagnosis. Particularly in the non-gastric EMZLs, concomitant involvement of multiple mucosal sites is not uncommon, with 25&#x000a0;to 50 percent of cases having disseminated disease. Bone marrow involvement is noted in up to 5&#x000a0;to 25 percent of patients and more common in non-gastric EMZLs.<xref ref-type="bibr" rid="article-25327.r32">[32]</xref></p>
      </sec>
      <sec id="article-25327.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of EMZL is made after a morphologic, immunophenotypic, and genetic analysis of the biopsy specimen. Clinicians should aim to obtain the largest biopsy specimen, as small biopsy specimens and fine-needle aspirates may not provide adequate tissue for diagnosis. After the diagnosis of EMZL by an experienced hematopathologist, additional evaluation should include a history and physical exam, focusing on lymph node regions, eyes, ears, nose, throat, liver, and spleen. The blood work should include a complete blood count with differential, comprehensive metabolic panel along with lactate dehydrogenase and beta-2 microglobulin. Hepatitis B and C (HBV and HCV) serology and cryoglobulins in a patient who is HCV positive. The tumor biopsy should be tested for <italic toggle="yes">H. pylori,</italic> especially in the gastric EMZL. Protein electrophoresis, serum, and urine immunofixation may also be sent.</p>
        <p>Bone marrow aspirate and biopsy are highly recommended in EMZL, particularly in non-gastric lymphoma. Imaging should include computed tomography of the chest, abdomen, and pelvis; sometimes, imaging of the orbits and salivary glands are recommended depending on the primary. A positron emission tomography (PET) scan should be considered for the adequate staging of the lymphoma and also is helpful when clinical and laboratory data suggest transformation. Esophagogastroduodenoscopy (EGD) and endoscopic ultrasound (EUS) are also useful in gastric EMZL for appropriate staging. Anti-SSA/Ro and anti-SSB/La antibody evaluation should be done in patients with salivary gland involvement to rule out the association of Sjogren syndrome.</p>
        <p>The Lugano staging system is widely used for staging. Recently, additional staging systems like the Paris staging system are also being used.<xref ref-type="bibr" rid="article-25327.r33">[33]</xref>&#x000a0;Also, patients should be evaluated for nutritional and Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance scales for performance status.</p>
      </sec>
      <sec id="article-25327.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management of EMZL depends on the primary site of involvement. Broadly the treatment depends on if the EMZL is gastric or non-gastric EMZL.</p>
        <p><bold>Gastric EMZL</bold>The majority of patients usually present as early-stage in gastric EMZL. The treatment depends on the status of H. pylori.</p>
        <p>
<bold>Patients Positive for <italic toggle="yes">H. pylori</italic></bold>
</p>
        <p>The primary treatment is directed at the eradication of the <italic toggle="yes">H. pylori</italic> with antibiotics in early-stage gastric EMZL. The choice of therapy depends on the local antibiotic resistance of <italic toggle="yes">H. pylori</italic>. The antibiotic treatment resulted in the regression of lymphoma and long-term disease control in the majority of patients.<xref ref-type="bibr" rid="article-25327.r34">[34]</xref><xref ref-type="bibr" rid="article-25327.r35">[35]</xref>&#x000a0;The most commonly used regimen is a combination of proton pump inhibitor (PPI) with amoxicillin and clarithromycin administered for 10&#x000a0;to 14 days. The majority of patients successfully eradicate&#x000a0;<italic toggle="yes">H. pylori,</italic> but the remaining may need an additional course of antibiotics. The outcome of the eradication treatment should be checked by a urea breath test or a stool antigen test about 6 weeks after the eradication therapy. Gastric EMZL regression is noted in up to 75% of cases with histologic complete response.<xref ref-type="bibr" rid="article-25327.r34">[34]</xref>&#x000a0;The length of time necessary to obtain a remission varies significantly from a few weeks to years. Gastric EMZL, which demonstrates t(11;18), has a lower chance of responding to the antibiotic therapy and complete response.<xref ref-type="bibr" rid="article-25327.r36">[36]</xref></p>
        <p>
<bold>Response Evaluation</bold>
</p>
        <p>After confirming the eradication of <italic toggle="yes">H pylori</italic>, periodic upper gastrointestinal endoscopic evaluations are recommended at least every 3 months with multiple biopsies to evaluate for tumor response as well as for recurrence. Once the complete response is achieved on the histology, the endoscopic evaluation can be staggered to every 6 months and then yearly after the first 2 years since diagnosis.</p>
        <p>
<bold>Failure of Initial Treatment</bold>
</p>
        <p>About 20 percent of the patients do not respond to the initial antibiotic therapy and require additional therapy. The appropriate timing for the second-line therapy is not clear as the responses from initial therapy can be slow and sometimes take up to a year. Treatment options include radiation therapy or systemic therapy with immunotherapy or chemoimmunotherapy.</p>
        <p>
<bold>Patients Negative for <italic toggle="yes">H. pylori</italic></bold>
</p>
        <p>A minority of patients with gastric EMZL are negative for <italic toggle="yes">H. pylori</italic> at the time of diagnosis. The consensus on treatment differs slightly between the National Comprehensive Cancer Network (NCCN) and the European Society of Medical Oncologists (ESMO). While NCCN suggests the use of other modalities like radiation and systemic therapy, ESMO recommends a trial of <italic toggle="yes">H. pylori</italic> directed therapy as testing for <italic toggle="yes">H. pylori</italic> is not 100 percent sensitive where some patients can have false-negative test results.&#x000a0;</p>
        <p><bold>Advanced Gastric EMZL&#x000a0;</bold>Patients with advanced disease who are positive for <italic toggle="yes">H pylori</italic> are still treated with antibiotics for eradication. In symptomatic disease, immunotherapy/chemoimmunotherapy is used as initial therapy. Those without <italic toggle="yes">H. pylori</italic>&#x000a0;infections are usually treated with systemic therapy, and treatment is usually initiated when patients are symptomatic.</p>
        <p>
<bold>Non-gastric EMZL</bold>
</p>
        <p>The common sites of involvement of EMZL other than gastric are the ocular adnexa, lung, thyroid, lacrimal glands, salivary glands, breast, skin, small intestine, dura, and soft tissues as discussed above. The treatment usually depends on the stage. Patients with localized disease are usually treated with local therapy like radiation, and advanced disease is treated with systemic therapy like immunotherapy and chemoimmunotherapy, which are discussed below.&#x000a0;</p>
        <p>Unlike gastric EMZL, the benefit from antibiotic use is still unclear in some of the non-gastric EMZL. Doxycycline was used in patients with ocular adnexa EMZL with evidence of <italic toggle="yes">C. psittaci</italic> infection, an estimated progression-free survival (PFS) at 5 years was about 55 percent.<xref ref-type="bibr" rid="article-25327.r5">[5]</xref><xref ref-type="bibr" rid="article-25327.r37">[37]</xref></p>
        <p>
<bold>Radiation Therapy</bold>
</p>
        <p>Local radiation therapy results in high rates of remission in early non-gastric EMZL. The 5-year survival rates are greater than 90%.<xref ref-type="bibr" rid="article-25327.r38">[38]</xref><xref ref-type="bibr" rid="article-25327.r39">[39]</xref><xref ref-type="bibr" rid="article-25327.r40">[40]</xref><xref ref-type="bibr" rid="article-25327.r41">[41]</xref>&#x000a0;A total&#x000a0;dose of 25 to 30 Gy administered over three to four weeks is usually used, and recently a low dose of 24 Gy was also studied.<xref ref-type="bibr" rid="article-25327.r41">[41]</xref>&#x000a0;Long term complications related to radiation are rare and usually dependent on the dose of radiation as well as the site. The side effects are usually noted in patients who received ocular adnexa radiation, causing cataract, corneal ulceration, optic atrophy, and glaucoma.</p>
        <p>
<bold>Systemic Therapy</bold>
</p>
        <p>Systemic therapy is usually used in patients with advanced disease or if radiation is not feasible or if the disease progressed after local radiation.</p>
        <p>Rituximab, a CD20 monoclonal antibody, is used with or without chemotherapy. Single-agent rituximab therapy is well tolerated, and the overall responses are in the range of 80 percent.<xref ref-type="bibr" rid="article-25327.r42">[42]</xref><xref ref-type="bibr" rid="article-25327.r43">[43]</xref> The use of combination therapy with chemotherapy depends on the goals of therapy. There is an increased progression-free survival, but no overall survival (OS) is noted, and the combination therapy is noted to have increased toxicity. It is usually preferred in symptomatic patients with bulky disease and patients who prefer a longer treatment-free interval.<xref ref-type="bibr" rid="article-25327.r44">[44]</xref><xref ref-type="bibr" rid="article-25327.r45">[45]</xref>&#x000a0;An international phase III clinical trial with EMZL patients not responding to or not eligible for local radiation were enrolled to be treated randomly with chlorambucil with or without rituximab. A third arm was later incorporated with single-agent rituximab. The group, with combination chlorambucil with rituximab, when compared with single-agent chlorambucil, showed improved complete remission (79% vs. 63%) and a 5-year PFS (72% vs. 59%).</p>
        <p>When compared to single-agent rituximab, the combination rituximab and chlorambucil showed improved complete response (79% vs. 56%) and a 5-year PFS (72% vs. 57%). All three treatments have a similar 5-year OS rate.<xref ref-type="bibr" rid="article-25327.r44">[44]</xref><xref ref-type="bibr" rid="article-25327.r45">[45]</xref>&#x000a0;Bendamustine, in combination with rituximab (BR), is another treatment option. Two other randomized trials compared BR versus R-CHOP&#x000a0;(cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-CVP (cyclophosphamide, vincristine, and prednisone). BR resulted in equivalent efficacy with less toxicity.<xref ref-type="bibr" rid="article-25327.r46">[46]</xref><xref ref-type="bibr" rid="article-25327.r47">[47]</xref> It is also noted to have good activity in cases with t(11;18).</p>
        <p>Rituximab, in combination with lenalidomide, has shown promising activity in a phase II trial.<xref ref-type="bibr" rid="article-25327.r48">[48]</xref>&#x000a0;Anthracycline containing regimens are usually not required unless there is a transformation to a large cell lymphoma. Ibrutinib is another medication studied in MZL in a phase II trial, where responses are seen in about 48 percent of patients after progressing on the previous CD20 directed therapy.<xref ref-type="bibr" rid="article-25327.r49">[49]</xref>&#x000a0;Idelalisib also has been studied in relapsed and refractory MZL and has a modest response.<xref ref-type="bibr" rid="article-25327.r50">[50]</xref>&#x000a0;Autologous stem cell transplantation is considered in some fit patients who have clinically aggressive disease relapse.<xref ref-type="bibr" rid="article-25327.r51">[51]</xref></p>
        <p>Surgery is not recommended in patients with EMZL, as it may impair quality of life, especially with local treatments having a significantly high overall survival even at 10 years.&#x000a0;</p>
        <p>
<bold>Transformation</bold>
</p>
        <p>Indolent lymphomas, including EMZL, can transform into more aggressive high-grade large cell lymphoma. It should be suspected in patients who develop B symptoms (fever, weight loss, drenching night sweats), a significant elevation in LDH, or rapid growth of a lymph node. A concern for large cell transformation should be further evaluated by a biopsy and PET scan for appropriate staging and treatment considerations. PET scan also can help select the appropriate site to do the biopsy.</p>
      </sec>
      <sec id="article-25327.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis to consider are:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Reactive lesions</p>
          </list-item>
          <list-item>
            <p>Nodal and splenic marginal zone lymphoma</p>
          </list-item>
          <list-item>
            <p>Diffuse large B cell lymphoma</p>
          </list-item>
          <list-item>
            <p>Small cell lymphoma</p>
          </list-item>
          <list-item>
            <p>Mantle cell lymphoma</p>
          </list-item>
          <list-item>
            <p>Follicular lymphoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25327.s10" sec-type="Staging">
        <title>Staging</title>
        <p>Lugano staging system for the gastrointestinal tract lymphoma:</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage I: Confined to the GI tract (single primary or multiple, non-contiguous)</p>
          </list-item>
          <list-item>
            <p>Stage II: Extending into the abdomen &#x000a0; &#x000a0; II1: Local nodal involvement &#x000a0; &#x000a0; II2: Distant nodal involvement</p>
          </list-item>
          <list-item>
            <p>Stage IIE: Penetration of serosa to involve adjacent organs or tissues</p>
          </list-item>
          <list-item>
            <p>Stage IV: Disseminated extra-nodal involvement or concomitant supra-diaphragmatic nodal involvement</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25327.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>EMZL has a relatively good prognosis with median survival greater than 10 years. However, some patients with high-risk disease are more likely to progress. MALT-IPI is a prognostic score that may be able to identify high-risk patients.<xref ref-type="bibr" rid="article-25327.r52">[52]</xref></p>
        <p>The independent prognostic factors were identified:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age &#x0003e; 70 years</p>
          </list-item>
          <list-item>
            <p>Stage III or IV disease</p>
          </list-item>
          <list-item>
            <p>Serum lactate dehydrogenase greater than the upper limit of normal</p>
          </list-item>
        </list>
        <p>The patients are divided into three risk groups depending on the number of prognostic factors.</p>
        <list list-type="bullet">
          <list-item>
            <p>Low risk &#x02013; zero risk factors</p>
          </list-item>
          <list-item>
            <p>Intermediate risk &#x02013; one risk factor</p>
          </list-item>
          <list-item>
            <p>High risk &#x02013; two or more risk factors</p>
          </list-item>
        </list>
        <p>The prognosis of the patients depends on what group they fall into, and the 5 -year progression-free survival (PFS) and overall survival (OS) are as follows.</p>
        <list list-type="bullet">
          <list-item>
            <p>Low risk &#x02013; PFS 76%, OS 99%</p>
          </list-item>
          <list-item>
            <p>Intermediate risk &#x02013; PFS 63%, OS 93%</p>
          </list-item>
          <list-item>
            <p>High risk &#x02013; PFS 33%, OS 64%</p>
          </list-item>
        </list>
        <p>Also, the prognosis depends on the histological transformation to a high-grade lymphoma, where patients had lower five-year survival rates.<xref ref-type="bibr" rid="article-25327.r53">[53]</xref></p>
      </sec>
      <sec id="article-25327.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of MALT-lymphoma usually are related to the local organ involvement as well as associated with therapy. Some of the common complications noted include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastric bleeding&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Iron deficiency anemia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Gastric perforation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Obstruction</p>
          </list-item>
          <list-item>
            <p>Cachexia</p>
          </list-item>
          <list-item>
            <p>Therapy-related complications like a life-threatening infection, hospitalization, decreased blood counts, secondary cancers, etc.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25327.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should receive education regarding the diagnosis, prognosis, and available treatment options. Patients should be educated on the possible adverse side effects associated with the treatment. Education on lifestyle modifications, smoking cessation, diet, and exercise should be provided. Patients should be alerted to monitor the common symptoms of the disease like fever, drenching night sweats, swollen lymph nodes, unintentional weight loss. Cancer survivorship education, as well as education on long-term complications, should be provided.</p>
      </sec>
      <sec id="article-25327.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of MALT lymphoma is complex and needs an interprofessional team approach. Hematologists and oncologists are always involved in the care of these patients, but other interprofessional team members, including&#x000a0;radiation oncologists, pathologists, gastroenterologists, and radiologists, are also pivotal. It is recommended that these complex patients are discussed in a multidisciplinary tumor board for a consensus treatment plan. This approach will facilitate optimal patient care, individualized treatment decisions, and also improve enrollment in the clinical trials.</p>
        <p>Other allied health professionals, including the pharmacists, nurses, social workers, dieticians, physical therapists, also are involved in the care of these patients. Constant interaction and discussion between these health professionals improve the outcomes of these patients. Having oncology trained psychologists as part of&#x000a0;the team also plays a significant role in addressing psycho-social issues pertaining to the diagnosis and management of lymphomas. Family and friends are also involved in the care of the patient, and every effort should be made to communicate with them and educate them regarding the disease. [Level 5]</p>
      </sec>
      <sec id="article-25327.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25327&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25327">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25327/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25327">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25327.s16">
        <title>References</title>
        <ref id="article-25327.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghielmini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Zelenetz</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>May</month>
            <day>19</day>
            <volume>127</volume>
            <issue>20</issue>
            <fpage>2375</fpage>
            <page-range>2375-90</page-range>
            <pub-id pub-id-type="pmid">26980727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olszewski</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Castillo</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database.</article-title>
            <source>Cancer</source>
            <year>2013</year>
            <month>Feb</month>
            <day>01</day>
            <volume>119</volume>
            <issue>3</issue>
            <fpage>629</fpage>
            <page-range>629-38</page-range>
            <pub-id pub-id-type="pmid">22893605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bertoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vannata</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas.</article-title>
            <source>Clin Cancer Res</source>
            <year>2014</year>
            <month>Oct</month>
            <day>15</day>
            <volume>20</volume>
            <issue>20</issue>
            <fpage>5207</fpage>
            <page-range>5207-16</page-range>
            <pub-id pub-id-type="pmid">25320370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roggero</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mainetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bertoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Valsangiacomo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pedrinis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Borisch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Piffaretti</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Isaacson</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin.</article-title>
            <source>Hum Pathol</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>263</fpage>
            <page-range>263-8</page-range>
            <pub-id pub-id-type="pmid">10685647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Guidoboni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ponzoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Conciliis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dell'Oro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fleischhauer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Caggiari</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lettini</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Dal Cin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ieri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Freschi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Villa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Boiocchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dolcetti</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2004</year>
            <month>Apr</month>
            <day>21</day>
            <volume>96</volume>
            <issue>8</issue>
            <fpage>586</fpage>
            <page-range>586-94</page-range>
            <pub-id pub-id-type="pmid">15100336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lecuit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abachin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poyart</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pochart</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bengoufa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Feuillard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Berche</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lortholary</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Immunoproliferative small intestinal disease associated with Campylobacter jejuni.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Jan</month>
            <day>15</day>
            <volume>350</volume>
            <issue>3</issue>
            <fpage>239</fpage>
            <page-range>239-48</page-range>
            <pub-id pub-id-type="pmid">14724303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Czapiewski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Colak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kosmidis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tousseyn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sagaert</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Boudova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Oko&#x00144;</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morresi-Hauf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agostinelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pruneri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>MQ</given-names>
              </name>
              <name>
                <surname>Fend</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Achromobacter xylosoxidans in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe.</article-title>
            <source>Br J Haematol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>164</volume>
            <issue>6</issue>
            <fpage>804</fpage>
            <page-range>804-10</page-range>
            <pub-id pub-id-type="pmid">24372375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arcaini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Merli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Volpetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rattotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zaja</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.</article-title>
            <source>Clin Dev Immunol</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>638185</fpage>
            <pub-id pub-id-type="pmid">22956970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zintzaras</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Voulgarelis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moutsopoulos</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>The risk of lymphoma development in autoimmune diseases: a meta-analysis.</article-title>
            <source>Arch Intern Med</source>
            <year>2005</year>
            <month>Nov</month>
            <day>14</day>
            <volume>165</volume>
            <issue>20</issue>
            <fpage>2337</fpage>
            <page-range>2337-44</page-range>
            <pub-id pub-id-type="pmid">16287762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nocturne</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mariette</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Sj&#x000f6;gren Syndrome-associated lymphomas: an update on pathogenesis and management.</article-title>
            <source>Br J Haematol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>168</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-27</page-range>
            <pub-id pub-id-type="pmid">25316606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khalil</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Devesa</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Check</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Weisenburger</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Dores</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site.</article-title>
            <source>Br J Haematol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>165</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-77</page-range>
            <pub-id pub-id-type="pmid">24417667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bertoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Roggero</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The gastric marginal zone B-cell lymphoma of MALT type.</article-title>
            <source>Blood</source>
            <year>2000</year>
            <month>Jul</month>
            <day>15</day>
            <volume>96</volume>
            <issue>2</issue>
            <fpage>410</fpage>
            <page-range>410-9</page-range>
            <pub-id pub-id-type="pmid">10887100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Ferry</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Grove</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Ocular adnexal lymphoma. A clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type.</article-title>
            <source>Ophthalmology</source>
            <year>1995</year>
            <month>Dec</month>
            <volume>102</volume>
            <issue>12</issue>
            <fpage>1994</fpage>
            <page-range>1994-2006</page-range>
            <pub-id pub-id-type="pmid">9098307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosado</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Byrne</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fields</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dubovy</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Markoe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lossos</surname>
                <given-names>IS</given-names>
              </name>
            </person-group>
            <article-title>Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci.</article-title>
            <source>Blood</source>
            <year>2006</year>
            <month>Jan</month>
            <day>15</day>
            <volume>107</volume>
            <issue>2</issue>
            <fpage>467</fpage>
            <page-range>467-72</page-range>
            <pub-id pub-id-type="pmid">16166588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wislez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thabut</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Antoine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rabbat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Couderc</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Monnet</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Blanc</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Mal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bergeron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dusser</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Isra&#x000eb;l-Biet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Crestani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cadranel</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics and prognostic factors of pulmonary MALT lymphoma.</article-title>
            <source>Eur Respir J</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>1408</fpage>
            <page-range>1408-16</page-range>
            <pub-id pub-id-type="pmid">19541720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Saleem</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Al-Mondhiry</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms.</article-title>
            <source>Blood</source>
            <year>2005</year>
            <month>Mar</month>
            <day>15</day>
            <volume>105</volume>
            <issue>6</issue>
            <fpage>2274</fpage>
            <page-range>2274-80</page-range>
            <pub-id pub-id-type="pmid">15542584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rinaldi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chigrinova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Arcaini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bhagat</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Rancoita</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>De Campos</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Forconi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gascoyne</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Facchetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ponzoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Govi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Mollejo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piris</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Soulier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Canzonieri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gattei</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marasca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Franceschetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gaidano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uccella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tibiletti</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Dirnhofer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripodo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Doglioni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dalla Favera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kwee</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bertoni</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>Feb</month>
            <day>03</day>
            <volume>117</volume>
            <issue>5</issue>
            <fpage>1595</fpage>
            <page-range>1595-604</page-range>
            <pub-id pub-id-type="pmid">21115979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Remstein</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Dogan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Einerson</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Paternoster</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dewald</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Kurtin</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>12</issue>
            <fpage>1546</fpage>
            <page-range>1546-53</page-range>
            <pub-id pub-id-type="pmid">17122510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ye</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Attygalle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wotherspoon</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Charlotte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Speight</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goodlad</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lavergne-Slove</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin-Subero</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dogan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Isaacson</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>MQ</given-names>
              </name>
            </person-group>
            <article-title>Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma.</article-title>
            <source>Blood</source>
            <year>2003</year>
            <month>Aug</month>
            <day>01</day>
            <volume>102</volume>
            <issue>3</issue>
            <fpage>1012</fpage>
            <page-range>1012-8</page-range>
            <pub-id pub-id-type="pmid">12676782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jost</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ruland</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.</article-title>
            <source>Blood</source>
            <year>2007</year>
            <month>Apr</month>
            <day>01</day>
            <volume>109</volume>
            <issue>7</issue>
            <fpage>2700</fpage>
            <page-range>2700-7</page-range>
            <pub-id pub-id-type="pmid">17119127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fevery</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sagaert</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Noels</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hagens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Broeckx</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Billiau</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>De Wolf-Peeters</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marynen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination.</article-title>
            <source>Cancer Res</source>
            <year>2006</year>
            <month>May</month>
            <day>15</day>
            <volume>66</volume>
            <issue>10</issue>
            <fpage>5270</fpage>
            <page-range>5270-7</page-range>
            <pub-id pub-id-type="pmid">16707452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmid</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kirkham</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Diss</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Isaacson</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Splenic marginal zone cell lymphoma.</article-title>
            <source>Am J Surg Pathol</source>
            <year>1992</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>455</fpage>
            <page-range>455-66</page-range>
            <pub-id pub-id-type="pmid">1599024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dreyling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gallamini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arcaini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kluin-Nelemans</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ladetto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Gouill</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iannitto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wotherspoon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.</article-title>
            <source>Ann Oncol</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>857</fpage>
            <page-range>857-77</page-range>
            <pub-id pub-id-type="pmid">23425945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Conconi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pedrinis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cortelazzo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Motta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gospodarowicz</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ponzoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Devizzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Giardini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pinotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Capella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Guillermo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ambrosetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <collab>International Extranodal Lymphoma Study Group</collab>
            </person-group>
            <article-title>Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.</article-title>
            <source>Blood</source>
            <year>2003</year>
            <month>Apr</month>
            <day>01</day>
            <volume>101</volume>
            <issue>7</issue>
            <fpage>2489</fpage>
            <page-range>2489-95</page-range>
            <pub-id pub-id-type="pmid">12456507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tu</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Giannini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Judkins</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Schwalb</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Burack</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Yachnis</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Scheithauer</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Aug</month>
            <day>20</day>
            <volume>23</volume>
            <issue>24</issue>
            <fpage>5718</fpage>
            <page-range>5718-27</page-range>
            <pub-id pub-id-type="pmid">16009945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Servitje</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gallardo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Estrach</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pujol</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Sevilla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>P&#x000e9;triz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Peyr&#x000ed;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Romagosa</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases.</article-title>
            <source>Br J Dermatol</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>147</volume>
            <issue>6</issue>
            <fpage>1147</fpage>
            <page-range>1147-58</page-range>
            <pub-id pub-id-type="pmid">12452864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferry</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Zukerberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lucarelli</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hasserjian</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Preffer</surname>
                <given-names>FI</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Lymphoma of the ocular adnexa: A study of 353 cases.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>170</fpage>
            <page-range>170-84</page-range>
            <pub-id pub-id-type="pmid">17255761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teckie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chelius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lovie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Noy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Portlock</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma.</article-title>
            <source>Ann Oncol</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>1064</fpage>
            <page-range>1064-1069</page-range>
            <pub-id pub-id-type="pmid">28327924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>del Valle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Berdel</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Willich</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Reers</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hiddemann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Grothaus-Pinke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Reinartz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brockmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Temmesfeld</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>R&#x000fc;be</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Probst</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jaenke</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bodenstein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Junker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schultze</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heinecke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parwaresch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tiemann</surname>
                <given-names>M</given-names>
              </name>
              <collab>German Multicenter Study Group</collab>
            </person-group>
            <article-title>Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92.</article-title>
            <source>J Clin Oncol</source>
            <year>2001</year>
            <month>Sep</month>
            <day>15</day>
            <volume>19</volume>
            <issue>18</issue>
            <fpage>3861</fpage>
            <page-range>3861-73</page-range>
            <pub-id pub-id-type="pmid">11559724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gui</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis.</article-title>
            <source>Med Oncol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>661</fpage>
            <page-range>661-6</page-range>
            <pub-id pub-id-type="pmid">19565363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Mian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kalpadakis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pangalis</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Stathis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Porro</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Conconi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cortelazzo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gaidano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lopez Guillermo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Martelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McPhail</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Copie-Bergman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Jack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mazzucchelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ristow</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Habermann</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nowakowski</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41).</article-title>
            <source>Oncologist</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>1149</fpage>
            <page-range>1149-53</page-range>
            <pub-id pub-id-type="pmid">26268740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raderer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiesewetter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).</article-title>
            <source>CA Cancer J Clin</source>
            <year>2016</year>
            <season>Mar-Apr</season>
            <volume>66</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-71</page-range>
            <pub-id pub-id-type="pmid">26773441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruskon&#x000e9;-Fourmestraux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dragosics</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Morgner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wotherspoon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Jong</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Paris staging system for primary gastrointestinal lymphomas.</article-title>
            <source>Gut</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>912</fpage>
            <page-range>912-3</page-range>
            <pub-id pub-id-type="pmid">12740354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zullo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cristofari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Andriani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Francesco</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ierardi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tomao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stolte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vaira</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-10</page-range>
            <pub-id pub-id-type="pmid">19631287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stathis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bertoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Proserpio</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Capella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mazzucchelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pedrinis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pinotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type.</article-title>
            <source>Ann Oncol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>1086</fpage>
            <page-range>1086-93</page-range>
            <pub-id pub-id-type="pmid">19193705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wotherspoon</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Doglioni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Diss</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moschini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Boni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Isaacson</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori.</article-title>
            <source>Lancet</source>
            <year>1993</year>
            <month>Sep</month>
            <day>04</day>
            <volume>342</volume>
            <issue>8871</issue>
            <fpage>575</fpage>
            <page-range>575-7</page-range>
            <pub-id pub-id-type="pmid">8102719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Govi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dognini</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Licata</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Crocchiolo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Resti</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Ponzoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial.</article-title>
            <source>Br J Haematol</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>150</volume>
            <issue>2</issue>
            <fpage>226</fpage>
            <page-range>226-9</page-range>
            <pub-id pub-id-type="pmid">20433679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomita</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kodaira</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tachibana</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mizoguchi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Takada</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma.</article-title>
            <source>Radiother Oncol</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>90</volume>
            <issue>2</issue>
            <fpage>231</fpage>
            <page-range>231-5</page-range>
            <pub-id pub-id-type="pmid">19135751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wirth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gospodarowicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aleman</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Bressel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tsang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Specht</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Szpytma</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lennard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study.</article-title>
            <source>Ann Oncol</source>
            <year>2013</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>1344</fpage>
            <page-range>1344-51</page-range>
            <pub-id pub-id-type="pmid">23293112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruskon&#x000e9;-Fourmestraux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matysiak-Budnik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fabiani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cervera</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brixi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Le Malicot</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nion-Larmurier</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fl&#x000e9;jou</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Hennequin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Qu&#x000e9;ro</surname>
                <given-names>L</given-names>
              </name>
              <collab>Groupe d&#x02019;&#x000c9;tude des Lymphomes Digestifs (GELD) &#x00026; F&#x000e9;d&#x000e9;ration Francophone de Canc&#x000e9;rologie Digestive</collab>
            </person-group>
            <article-title>Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma: Results of a prospective study with a long term follow-up.</article-title>
            <source>Radiother Oncol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>117</volume>
            <issue>1</issue>
            <fpage>178</fpage>
            <page-range>178-82</page-range>
            <pub-id pub-id-type="pmid">26395311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinnix</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Gunther</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Milgrom</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Cruz Chamorro</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Khoury</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Amini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Neelapu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Westin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nastoupil</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dabaja</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2019</year>
            <month>Jun</month>
            <day>01</day>
            <volume>104</volume>
            <issue>2</issue>
            <fpage>447</fpage>
            <page-range>447-455</page-range>
            <pub-id pub-id-type="pmid">30769175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Laszlo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Pruneri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ponzoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Conconi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crosta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pedrinis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bertoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Calabrese</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Mar</month>
            <day>20</day>
            <volume>23</volume>
            <issue>9</issue>
            <fpage>1979</fpage>
            <page-range>1979-83</page-range>
            <pub-id pub-id-type="pmid">15668468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Datta</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kampalath</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Binion</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Rituximab-induced remission of a gastric MALT lymphoma.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>1297</fpage>
            <page-range>1297-9</page-range>
            <pub-id pub-id-type="pmid">15360017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Conconi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laszlo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Guillermo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bouabdallah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Coiffier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sebban</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jardin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vitolo</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Morschhauser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Copie-Bergman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Floriani</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Martelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2013</year>
            <month>Feb</month>
            <day>10</day>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>565</fpage>
            <page-range>565-72</page-range>
            <pub-id pub-id-type="pmid">23295789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Conconi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bouabdallah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vitolo</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Martelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pettengell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sebban</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guillermo</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Pinotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Devizzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Morschhauser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tilly</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Torri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hohaus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJM</given-names>
              </name>
              <name>
                <surname>Zach&#x000e9;e</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bosly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haioun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stelitano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bellei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ponzoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moreau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mazzucchelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.</article-title>
            <source>J Clin Oncol</source>
            <year>2017</year>
            <month>Jun</month>
            <day>10</day>
            <volume>35</volume>
            <issue>17</issue>
            <fpage>1905</fpage>
            <page-range>1905-1912</page-range>
            <pub-id pub-id-type="pmid">28355112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rummel</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Niederle</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maschmeyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Banat</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>von Gr&#x000fc;nhagen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Losem</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kofahl-Krause</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Heil</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Welslau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Balser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Weidmann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>D&#x000fc;rk</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ballo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stauch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roller</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoelzer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hinke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brugger</surname>
                <given-names>W</given-names>
              </name>
              <collab>Study group indolent Lymphomas (StiL)</collab>
            </person-group>
            <article-title>Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.</article-title>
            <source>Lancet</source>
            <year>2013</year>
            <month>Apr</month>
            <day>06</day>
            <volume>381</volume>
            <issue>9873</issue>
            <fpage>1203</fpage>
            <page-range>1203-10</page-range>
            <pub-id pub-id-type="pmid">23433739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flinn</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>van der Jagt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kahl</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hertzberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kolibaba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Issa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clementi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hallman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Munteanu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.</article-title>
            <source>Blood</source>
            <year>2014</year>
            <month>May</month>
            <day>08</day>
            <volume>123</volume>
            <issue>19</issue>
            <fpage>2944</fpage>
            <page-range>2944-52</page-range>
            <pub-id pub-id-type="pmid">24591201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiesewetter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Willenbacher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Willenbacher</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Egle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Neumeister</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Voskova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mayerhoefer</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Simonitsch-Klupp</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Melchardt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Greil</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raderer</surname>
                <given-names>M</given-names>
              </name>
              <collab>AGMT Investigators</collab>
            </person-group>
            <article-title>A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Jan</month>
            <day>19</day>
            <volume>129</volume>
            <issue>3</issue>
            <fpage>383</fpage>
            <page-range>383-385</page-range>
            <pub-id pub-id-type="pmid">27879257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Vos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Flowers</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Morschhauser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peles</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barrientos</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Munneke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dimery</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Beaupre</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Apr</month>
            <day>20</day>
            <volume>129</volume>
            <issue>16</issue>
            <fpage>2224</fpage>
            <page-range>2224-2232</page-range>
            <pub-id pub-id-type="pmid">28167659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gopal</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kahl</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>de Vos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wagner-Johnston</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Jurczak</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Flinn</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>Flowers</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Viardot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Goy</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Dreyling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Holes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dansey</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Godfrey</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>PI3K&#x003b4; inhibition by idelalisib in patients with relapsed indolent lymphoma.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Mar</month>
            <day>13</day>
            <volume>370</volume>
            <issue>11</issue>
            <fpage>1008</fpage>
            <page-range>1008-18</page-range>
            <pub-id pub-id-type="pmid">24450858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avivi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Arcaini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ferretti</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Boumendil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Finel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Milone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zaja</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Liliana</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Musso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Didier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bachy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wattad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nicolas-Virelizier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gramatzki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bourhis</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Caillot</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haenel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Held</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jindra</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pohlreich</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guilhot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kroschinsky</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wahlin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Scheid</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ifrah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Berthou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dreger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Montoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Conconi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.</article-title>
            <source>Br J Haematol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>182</volume>
            <issue>6</issue>
            <fpage>807</fpage>
            <page-range>807-815</page-range>
            <pub-id pub-id-type="pmid">29984825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cascione</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Conconi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kiesewetter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Raderer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gaidano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laszlo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Coiffier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lopez Guillermo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Torri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>A MALT lymphoma prognostic index.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Sep</month>
            <day>21</day>
            <volume>130</volume>
            <issue>12</issue>
            <fpage>1409</fpage>
            <page-range>1409-1417</page-range>
            <pub-id pub-id-type="pmid">28720586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25327.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alderuccio</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gallastegui</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ramdial</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kimble</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de la Fuente</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Rosenblatt</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Vega</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Lossos</surname>
                <given-names>IS</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution.</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>12</day>
            <fpage>JCO1800138</fpage>
            <pub-id pub-id-type="pmid">30312133</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
